可溶性fms样酪氨酸激酶-1与胎盘生长因子比值:排除子痫前期长达4周及重复检测的价值
本研究为PROGNOSIS研究的事后探索性分析,纳入550例疑似子痫前期孕妇。sFlt-1/PlGF比值≤38排除2周和3周内子痫前期的阴性预测值分别为97.9%和95.7%,排除4周内子痫前期的阴性预测值为94.3%,灵敏度和特异度分别为66.2%和83.1%。发生子痫前期者比值升高幅度显著大于未发生者。
要点
- sFlt-1/PlGF比值≤38可排除2周和3周内子痫前期,阴性预测值分别为97.9%和95.7%。
- 比值≤38排除4周内子痫前期的阴性预测值为94.3%,灵敏度66.2%,特异度83.1%。
- 发生子痫前期者2周和3周时比值升高幅度均显著大于未发生者。
核心结论
- Elecsys®免疫分析法检测的sFlt-1/PlGF比值有助于在疑似子痫前期孕妇中排除4周内子痫前期的发生。
研究设计与样本
- PROGNOSIS研究的事后探索性分析,纳入年龄≥18岁、首次就诊时孕24+0至36+6周、疑似子痫前期的孕妇,共分析550例。
- 首次就诊时及此后每周采集血清样本,使用Elecsys® sFlt-1和PlGF免疫分析法检测。
主要发现
- sFlt-1/PlGF比值≤38排除基线后2周和3周内子痫前期的阴性预测值分别为97.9%和95.7%。
- sFlt-1/PlGF比值≤38排除4周内子痫前期的阴性预测值为94.3%,灵敏度和特异度分别为66.2%和83.1%。
- 发生子痫前期者较未发生者,首次就诊后2周比值中位升高幅度为31.22 vs 1.45(P < 0.001),3周为48.97 vs 2.39(P < 0.001)。
- 发生子痫前期和/或不良胎儿结局者较未发生者,2周比值中位升高幅度为21.22 vs 1.40(P < 0.001),3周为34.95 vs 2.30(P < 0.001)。
关键数值与推荐
- sFlt-1/PlGF比值 cut-off ≤ 38用于排除1周内子痫前期(源于PROGNOSIS研究验证)。
- sFlt-1/PlGF比值≤38排除2周内子痫前期阴性预测值97.9%,排除3周内阴性预测值95.7%。
- sFlt-1/PlGF比值≤38排除4周内子痫前期阴性预测值94.3%,灵敏度66.2%,特异度83.1%。
临床怎么用
- 作者认为Elecsys®免疫分析法检测的sFlt-1/PlGF比值有助于在疑似子痫前期孕妇中排除4周内子痫前期的发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF) ratio is generally elevated some time before and at the clinical onset of pre-eclampsia. The PROGNOSIS study validated a sFlt-1/PlGF ratio cut-off of ≤ 38 to rule out the onset of pre-eclampsia within 1 week of testing in women with suspected disease. The aim of this study was to assess the predictive value of the sFlt-1/PlGF ratio to rule out the onset of pre-eclampsia for up to 4 weeks, and to assess the value of repeat measurements. METHODS: This was an exploratory post-hoc analysis of data from the PROGNOSIS study performed in pregnant women aged ≥ 18 years with suspected pre-eclampsia, who were at 24 + 0 to 36 + 6 weeks' gestation at their first clinic visit. Serum samples were collected at the first visit and weekly thereafter. sFlt-1 and PlGF levels were measured using Elecsys® sFlt-1 and PlGF immunoassays. Whether the sFlt-1/PlGF ratio cut-off of ≤ 38 used to rule out the onset of pre-eclampsia within 1 week could predict the absence of pre-eclampsia 2, 3, and 4 weeks post-baseline was assessed. The value of repeat sFlt-1/PlGF testing was assessed by examining the difference in sFlt-1/PlGF ratio 2 and 3 weeks after the first measurement in women with, and those without, pre-eclampsia or adverse fetal outcome. RESULTS: On analysis of 550 women, sFlt-1/PlGF ratio ≤ 38 ruled out the onset of pre-eclampsia 2 and 3 weeks post-baseline with high negative predictive values (NPV) of 97.9% and 95.7%, respectively. The onset of pre-eclampsia within 4 weeks was ruled out with a high NPV (94.3%) and high sensitivity and specificity (66.2% and 83.1%, respectively). Compared with women who did not develop pre-eclampsia, those who developed pre-eclampsia had significantly larger median increases in sFlt-1/PlGF ratio at 2 weeks (∆, 31.22 vs 1.45; P < 0.001) and at 3 weeks (∆, 48.97 vs 2.39; P < 0.001) after their initial visit. Women who developed pre-eclampsia and/or adverse fetal outcome compared with those who did not had a significantly greater median increase in sFlt-1/PlGF ratio over the same period (∆, 21.22 vs 1.40; P < 0.001 at 2 weeks; ∆, 34.95 vs 2.30; P < 0.001 at 3 weeks). CONCLUSION: The Elecsys® immunoassay sFlt-1/PlGF ratio can help to rule out the onset of pre-eclampsia for 4 weeks in women with suspected pre-eclampsia. © 2018 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Zeisler H, Llurba E, Chantraine FJ, et al. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Ultrasound Obstet Gynecol. 2019. PMID: 30014562. doi:10.1002/uog.19178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。